TCON has done a lot with very little - management has been impressive.
Pretty sure the drug is active, but developing a combination oncology therapy in multiple indications is challenging for such a small company with limited resources. It's harder that the drug works well in only some subset of patients - I recall way back when when one of their first patients in a monotherapy trial had a complete response with late-stage metastatic prostate cancer.
Market Data 
Markets 
AI
